MECFA Blog

News & Articles

Dietary Flavonoids May Help in Managing CF Through Impact on Gut Bacteria, Small Study Suggests

Consuming dietary flavonoids — compounds naturally found in fruits, vegetables, chocolate, and beverages like wine and tea — may be associated with changes in gut bacteria that potentially affect the body’s metabolism, immune function, and inflammation in patients with cystic fibrosis (CF), a small study reports. The flavonoid-related changes in the gut microbiota may influence the management of lung disease and comorbidity (other disorders) in CF patients, its researchers said, particularly stressing the need to investigate the role of black tea, rich in specific flavonoids, in CF nutrition therapy. The study “Associations between Flavonoid Intakes and Gut Microbiota in a Group of Adults wi

Take the MECFA Survey!

Dear MECFA Members and Friends, The Middle East Cystic Fibrosis Association (MECFA) is non profit organization dedicated to improving quality of life and life expectancy for people with CF in the Middle East. A primary focus of MECFA is to establish CF centers and expand treatment options in the region. The Middle East has a lot of variation in terms of available resources for CF patients. Therefore, we developed a survey in order to have a better understanding of the situation for CF patients in each country. We are asking clinicians and allied health professionals who are currently working with CF patients in the Middle East to complete the survey. Your responses will help us understand th

Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients

Editor’s Note: This is the second of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we detail the steps that made three disease-modifying oral treatments for cystic fibrosis possible. Kalydeco (ivacaftor), as Vertex‘s cystic fibrosis potentiator came to be known, was a small molecule compound that posed big questions upon its discovery in the mid-2000s. Should researchers go ahead and test it in those few patients — about 3 percent worldwide — with a rare gating mutation known as G551D? Should they plow on in pursuit of a paired corrector, a double combination that might treat many more — some 40 percent — with the F508 deletion mutation? These w

Discovering the ancient origin of cystic fibrosis, the most common genetic disease in Caucasians

Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF), results in tracing it to a group of distinct but mysterious Europeans who lived about 5,000 years ago. CF is the most common, potentially lethal, inherited disease among Caucasians – about one in 40 carry the so-called F508del mutation. Typically only beneficial mutations, which provide a survival advantage, spread widely through a population. CF hinders the release of digestive enzymes from the pancreas, which triggers malnutrition, causes lung disease that is eventually fatal and produces high levels of salt in sweat that can be life-threatening. In recent ye

Vertex and Treating CF: Stepping Out on Long Road to ‘Medical History’

Editor’s note: This is the first of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. We begin by recounting the discoveries that made three disease-modifying treatments for cystic fibrosis — by the same science team — possible in a matter of years. To the interested public, Vertex Pharmaceuticals is known as the cystic fibrosis company — the group that, as its slogan implies, is “all in for CF.” Rightly, the company is quick to note other treatments in its development pipeline, mainly for acute pain and spinal cord injury, and that it’s working in other “difficult disease areas” like sickle cell disease and that of alpha antitrypsin, a genetic disorder o

Telavancin Promising Potential Treatment Option for MRSA in Cystic Fibrosis Patients

Responsible for several issues ranging from skin infections and sepsis to pneumonia and bloodstream infections, methicillin-resistant Staphylococcus aureus continues to plague patients in the health care and community setting, as well as the providers who treat them. When acquired in patients with cystic fibrosis, clinical outcomes are known to be even worse, affecting several organs—primarily the lungs—and resulting in an increased rate of declined respiratory function as well as infections that can have severe, and sometimes deadly, consequences. Now, however, for the first time, investigators have found that telavancin—a drug that is currently used to treat skin infections and hospita

Committee approves 8 additional conditions for treatment with medical marijuana

A legislative committee approved eight additional conditions — six just for adults and two for adults and children — that will soon be legal for treatment with medical marijuana under state law on Tuesday. Adults seeking a medical marijuana card to purchase products at one of the state's nine medical marijuana dispensaries soon may apply to the program based on a diagnosis of the eight newly added conditions, mostly illnesses that cause chronic pain and headaches. The additions to the list will be finalized when the secretary of the state's office amends the medical marijuana regulations later this week, said Lora Rae Anderson, a spokesperson for the state Department of Consumer Protection,

MRSA Difficult to Eradicate, Even With Multimodal Antibiotics, CF Study Finds

Up to one month of treatment with inhaled vancomycin, the antibiotic of choice for treating most methicillin-resistant Staphylococcus aureus (MRSA) infections, together with a combination of oral and topical antibiotics, failed to clear infection in cystic fibrosis (CF) patients at better rates than the antibiotic combination alone, results from a Phase 2 clinical trial show. The study “Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis” was published in the Journal of Cystic Fibrosis. The prevalence of MRSA in CF patients has increased in the past two decades, and it is estimated that currently 26 percent of CF patients in the U.S. are infecte

DarioHealth Chosen by Attain Health for Pilot Study to Improve Cystic Fibrosis Related Diabetes Mana

- Opportunity for DarioHealth to take early lead in deploying digital health solution for this unique form of diabetes common in people with cystic fibrosis - Preliminary results to be presented at North American Cystic Fibrosis Conference in October 2018 CAESAREA, Israel, Aug. 22, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ : DRIO ), a leading global digital health company with mobile health and big data solutions, announced today it has entered into an agreement with Attain Health, a provider of integrative health coaching for individuals living with cystic fibrosis, to pilot the DarioEngage platform for the management of cystic fibrosis related diabetes (CFRD). CFRD is a unique from of

FDA Expands Kalydeco’s Approval to 1-year-old Toddlers with Cystic Fibrosis

The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) as the first-ever therapy to treat the underlying cause of cystic fibrosis (CF) in 1-year-old toddlers, Vertex Pharmaceuticals announced. “Parents and physicians now have a medicine to treat the underlying cause of CF in patients as young as one year of age,” Reshma Kewalramani, MD, Vertex’s executive vice president and chief medical officer, said in a press release. People with CF have mutations in the CFTR gene, which lead to the absence, reduction, or faulty CFTR, a protein channel involved in the regulation of salt and water transport in and out of cells. These mutations result in thick, sticky secretions and m

Vertex Wins FDA Approval for Expanded Cystic Fibrosis Treatment

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares saw a handy gain on Thursday after the U.S. Food and Drug Administration (FDA) gave the nod to Vertex’s cystic fibrosis (CF) treatment. Essentially, the FDA approved Kalydeco (ivacaftor) to include use in children diagnosed with CF ages 12 to 24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. This FDA approval is based on data from the ongoing Phase 3 study (ARRIVAL) of 25 children with CF aged 12 to 24 months who have one of 10 mutations in the CFTR gene. The study demonstrated a safety profile consistent with that observed in previous Phase 3 studies of older children and adult

ELITechGroup Biomedical Systems, World Leader for Laboratory Diagnosis of Cystic Fibrosis, Launches

LOGAN, Utah--(BUSINESS WIRE)--Aug 16, 2018--ELITechGroup Biomedical Systems (EBS), known for worldwide transformation and innovation of sweat testing with the Webster Sweat Inducer and Macroduct® Sweat Collection System, endorsed by the U.S. Cystic Fibrosis Foundation and other global CF associations, announces the release of the new FDA-cleared Macroduct® Advanced Sweat Collection System. Features of the new Macroduct Advanced include a touch screen user interface with built-n step-by-step graphical instructions that further standardize pilocarpine iontophoresis and sweat collection for optimum results. In addition, the revised shape of electrodes and Macroduct collector offer greater conve

IRT Test

Cystic fibrosis is caused by mutations in the CFTR gene, which results in thick mucus building up around organs and tissues. This is especially dangerous in the lungs, as it can lead to inflammation, infection, and the formation of scar tissue. Early diagnosis and treatment are key to minimizing the impact of the disease and maintaining patients’ quality of life. What Is the IRT test? Immunoreactive trypsinogen (IRT) is an enzyme precursor that is normally made in the pancreas. In cystic fibrosis, IRT can be secreted at higher levels into the bloodstream because of blockages in the pancreatic ducts. IRT tests are part of standard newborn blood screens in the U.S. and the U.K. IRT levels can

Orkambi Not Seen to Significantly Improve Blood Glucose Levels in CF Patients in Small Study

Analysis of blood glucose levels in cystic fibrosis (CF) patients being treated with Orkambi (ivacaftor/lumacaftor) shows that the therapy has minimal impact on glycemic control, a small study reports. Up to 50 percent of adults with cystic fibrosis develop diabetes, making so-called CF-related diabetes (CFRD) the most common comorbidity, or coexisting condition, in these patients. The molecular mechanism behind CFRD development is still under investigation, but it is believed to be linked to the cystic fibrosis transmembrane conductance regulator protein (CFTR), the protein that is altered in CF and that is present in pancreatic cells that normally produce insulin. Therefore, treatments tha

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean